Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Bulbo-Spinal Atrophy, X-Linked × darolutamide × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 13 Biochemically Recurrent Prostate Cancer 2 Urogenital Neoplasms 1 Urogenital Diseases 1 Prostatic Neoplasms, Castration-Resistant 1 Prostatic Diseases 1 Non-metastatic Castration-resistant Prostate Cancer 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Male Urogenital Diseases 1 High-Risk Localized Prostate Cancer 1 Granulosa cell tumor of the ovary 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

darolutamide 1 abiraterone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07190300 2026-03-02

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting

Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡